The practice of using combinations of drugs in chemotherapy is not new and continues to evolve to include immune checkpoint inhibitors. Drug combinations can be more effective than single-agent therapy and may also reduce the risk of developing resistance. However, combining multiple drugs may increase the risk of drug interactions. Please join Laura Wood, RN, MSN, OCN, Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, as they discuss how they have a conversation with their patients about the benefits and risks of using drug combinations in anticancer therapy.
Baylor Charles A. Sammons Cancer Center
Dallas, TX
Dallas, TX
Beth Israel Deaconess Medical Center
Boston, MA
Boston, MA
Cleveland Clinic Taussig Cancer Center
Cleveland, OH
Cleveland, OH
Advanced Care Practitioners Take a Lead in Improving Quality of Life and Patient Satisfaction for Cancer PatientsMaintaining quality of life for cancer patients means different things to different cancer patients. However, the conversation starts with helping patients manage their expectations regarding their therapy and how it will impact their quality of life. Please join Laura Wood, RN, MSN, OCN, Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, as they examine the many ways that they collaborate with their oncology team colleagues to assess and review how an individual patient’s treatment regimen is influencing that patient’s quality of life.
Talking to Cancer Patients About Combination ChemotherapyThe practice of using combinations of drugs in chemotherapy is not new and continues to evolve to include immune checkpoint inhibitors. Drug combinations can be more effective than single-agent therapy and may also reduce the risk of developing resistance. However, combining multiple drugs may increase the risk of drug interactions. Please join Laura Wood, RN, MSN, OCN, Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, as they discuss how they have a conversation with their patients about the benefits and risks of using drug combinations in anticancer therapy.
